Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder

Overview of attention for article published in Psychopharmacology, April 2017

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 47 Dimensions

Readers on

mendeley: 125 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 7,606 followers.

RT @VirBoso: Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressan…

15 Jan 2018

Reply Repost Favourite

Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder https://t.co/FZL4Y2CycU

15 Jan 2018

Reply Repost Favourite

CNSDose (ABCB1, ABCC1, CYP2C19, CYP2D6, UGT1A1) is the only pharmacogenomics test that improved remission of a MDE https://t.co/Xdk1kBKKQI

30 May 2017

Reply Repost Favourite

個人の遺伝的特性にあった抗うつ薬によるうつ病治療。レビュー。Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness…https://t.co/9eUnrTztKc

01 May 2017

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.